statistical_reproducibility.md
329 lines · skills/peer-review/references/statistical_reproducibility.md at 5f2bc03
Most marks come from matching words in the file, so treat them as pointers.
Statistical, Methods, and Reproducibility Review
This guide supports structured questions; it does not replace a statistician, methodologist, domain expert, or independent reanalysis. Sources reviewed on 2026-10-01, with source-specific verification limits, are recorded in assets/source_ledger.csv.
Evidence hierarchy for the review
Use, in order:
- The stated research question and target population
- Protocol, registration, analysis plan, and amendments
- Reported design and data-generating process
- Methods, code, tables, figures, supplements, and repository records
- Applicable primary method or regulatory guidance
- Current reporting guidance
- Target venue policy
Do not reject a method merely because another method is more familiar. Explain the estimand, assumption, error, or interpretation at stake.
Raw lines 5 to 18Core review sequence
Raw lines 19 to 201. Define what is being estimated
Write down:
- Unit of inference
- Population
- Intervention, exposure, test, or predictors
- Comparator or reference condition
- Outcome and time horizon
- Target effect, association, accuracy, or predictive performance
- Intercurrent events, censoring, and missing observations where relevant
Then trace whether design, data collection, analysis, result, and claim target the same quantity.
For applicable clinical trials, ICH E9(R1) provides a framework for estimands and sensitivity analyses. It is not a universal rule for every study.
Raw lines 21 to 362. Reconstruct the design
Identify:
- Prospective, retrospective, cross-sectional, longitudinal, experimental, or observational structure
- Recruitment or sampling frame
- Experimental/observational unit
- Pairing, nesting, clustering, repeated measures, sites, batches, and time
- Allocation, concealment, blinding, matching, or weighting
- Primary and secondary outcomes
- Prespecified versus exploratory analyses
If the design cannot be reconstructed, first request missing reporting. Do not label the design invalid solely because details are absent.
Raw lines 37 to 503. Trace every denominator
Reconcile:
- Eligible, enrolled, assigned, treated/exposed, followed, measured, and analyzed units
- Outcome-specific denominators
- Exclusions before and after allocation or measurement
- Missing values and reasons
- Complete-case, imputed, weighted, or model-based analysis populations
- Figure, table, abstract, text, and supplement totals
Report the exact mismatch and locations; do not infer why counts differ.
Raw lines 51 to 634. Assess analysis–design alignment
Ask whether the method accounts for:
- Outcome scale and distribution
- Pairing and repeated measures
- Clustering and multilevel structure
- Unequal follow-up, censoring, or competing events
- Sampling weights or matched designs
- Baseline adjustment and prespecified covariates
- Multiplicity and outcome hierarchy
- Model tuning and validation
- Missingness assumptions
The name of a statistical test is not enough. The report should state inputs, model form, uncertainty method, software/version, and relevant diagnostics.
Raw lines 64 to 795. Assess estimates and interpretation
Prefer:
- Effect or performance estimates with units
- Compatible uncertainty intervals
- Absolute as well as relative quantities when decision-relevant
- Exact denominators and analysis sets
- Assumption and sensitivity context
- Clinical, biological, policy, or practical relevance distinct from statistical compatibility
The ASA’s six p-value principles include:
- A p-value is about incompatibility with a specified model, not the probability a hypothesis is true.
- Threshold crossing alone should not determine scientific conclusions.
- Transparent reporting of all relevant analyses is required.
- Statistical significance does not measure effect size or importance.
- A p-value alone is not a good measure of evidence.
SAMPL provides concise biomedical statistical reporting guidance. Apply it as reporting guidance, not a universal analysis recipe.
Raw lines 80 to 100Topic-specific checks
Raw lines 101 to 102Sample size and precision
Look for:
- Prospective calculation or precision rationale
- Target effect or interval width
- Variance, event rate, prevalence, or accuracy assumptions
- Type I error, power, sidedness, and multiplicity when applicable
- Design effect, clustering, attrition, noncompliance, and missingness
- Model complexity and effective sample size
- Simulation details for complex designs
Do not request observed/post hoc power as a remedy for an imprecise result. Examine the estimate and uncertainty.
Raw lines 103 to 116Randomized trials
Check:
- Allocation sequence and concealment
- Prespecified estimand and analysis population
- Protocol/registry/outcome consistency
- Baseline adjustment and stratification factors
- Intercurrent events, adherence, treatment switching, and missing data
- Harms and unintended effects
- Sensitivity and supplementary analyses
- Non-inferiority/equivalence margin and interpretation if relevant
Use CONSORT 2025 and SPIRIT 2025 for reporting. Use ICH E9/E9(R1) only when its scope and decision context fit.
Raw lines 117 to 131Observational causal analyses
Check:
- Causal question and target contrast
- Time zero, eligibility, treatment/exposure assignment, follow-up, and outcome timing
- Confounder rationale and measurement timing
- Positivity/overlap
- Exchangeability and consistency assumptions
- Missingness, censoring, selection, and measurement error
- Model specification and balance diagnostics
- Sensitivity to unmeasured confounding or alternative specifications
Avoid judging causal identification from adjusted versus unadjusted p-values.
Raw lines 132 to 146Diagnostic accuracy
Check:
- Intended use, setting, and participant spectrum
- Index test and reference standard
- Threshold prespecification
- Blinding and timing
- Indeterminate/missing results
- Verification and incorporation bias
- Two-by-two denominators and uncertainty
- External applicability
STARD/STARD-AI describe reporting; use an appropriate risk-of-bias framework separately.
Raw lines 147 to 161Prediction models
Check:
- Intended use, prediction time, outcome, and target population
- Data source and participant flow
- Predictor availability at intended use
- Missing-data and preprocessing leakage
- Sample size relative to outcome information and complexity
- Internal validation and optimism correction
- Independent evaluation and dataset shift
- Calibration, discrimination, decision utility, and uncertainty
- Hyperparameter tuning separated from evaluation
- Reproducible model specification and preprocessing
- Subgroup performance tied to plausible use and harms
TRIPOD+AI replaces TRIPOD 2015 for regression and machine-learning prediction model reporting. STARD-AI is more appropriate when diagnostic accuracy of an index test is the primary aim.
Raw lines 162 to 179Systematic reviews and meta-analyses
Check:
- Protocol and registration
- Eligibility criteria and information sources
- Reproducible search dates and strategies
- Duplicate screening/extraction processes or justified alternatives
- Risk-of-bias assessment
- Effect measure and synthesis model
- Heterogeneity and prediction intervals when appropriate
- Dependence among estimates
- Small-study and reporting biases
- Certainty assessment, if claimed
- Transparent deviations and unavailable data
PRISMA 2020 assesses reporting. Do not substitute PRISMA coverage for review-conduct appraisal.
Raw lines 180 to 197Clustered and longitudinal data
Check:
- Level of assignment, measurement, and inference
- Within-cluster/subject correlation
- Number and distribution of clusters
- Small-cluster corrections where needed
- Time structure, nonlinear change, and irregular measurement
- Informative visit, dropout, or censoring processes
- Cluster-level versus individual-level covariates
Repeated observations do not increase independent sample size one-for-one.
Raw lines 198 to 211Multiplicity
Identify the inferential family before recommending adjustment:
- Multiple primary outcomes
- Multiple intervention arms or contrasts
- Repeated time points
- Subgroups and interactions
- Interim analyses
- High-dimensional features
- Model selection
Possible responses include hierarchical testing, family-wise control, false-discovery control, multilevel modeling, transparent exploratory labeling, or emphasis on estimates and uncertainty. The remedy depends on the claim and decision rule.
Raw lines 212 to 225Missing data
Check:
- Missingness by group, variable, outcome, and time
- Reasons and relation to intercurrent events
- Information used by imputation or weighting
- Number of imputations and pooling when applicable
- Compatibility of imputation and analysis models
- Uncertainty propagation
- Sensitivity to plausible departures from assumptions
Avoid demanding one preferred technique without considering the estimand and missingness process.
Raw lines 226 to 239Reproducibility review
Raw lines 240 to 241Materials and provenance
Check:
- Stable identifiers for datasets, samples, models, protocols, and materials
- Raw-to-processed provenance
- Exclusion and transformation records
- Versioned analysis inputs and outputs
- Repository accession numbers
- Data dictionary, units, and coding
- Domain metadata standard where applicable
Legacy domain standards and their current status are summarized in references/reporting_standards.md.
Code and computational environment
Check:
- Executable code for central analyses when sharing is permitted
- Dependency versions or lock/environment file
- Operating-system or hardware requirements that affect results
- Random seeds and nondeterminism
- Parameter, configuration, and model checkpoints
- Run order and instructions
- Tests or validation of custom code
- License and access restrictions
Code availability does not prove that the code generated the reported result. Provenance and a reproducible run record are separate evidence.
Raw lines 256 to 270Data and access
Open sharing may be limited by consent, privacy, indigenous/community governance, security, contracts, or licensing. A useful statement should identify:
- What exists
- Where it is held
- Who can request access
- Criteria and process
- Expected timeline
- Restrictions and rationale
- Whether code or synthetic/aggregate alternatives are available
Do not request disclosure that would violate ethics, law, consent, or governance.
Raw lines 271 to 284Independent reproduction
Claim independent reproduction only if the reviewer actually:
- Obtained authorized inputs.
- Recorded versions and environment.
- Ran documented commands.
- Preserved content hashes or equivalent provenance.
- Compared prespecified outputs.
- Recorded deviations and failures.
A static consistency audit is not reproduction.
Raw lines 285 to 297When to request specialist review
Escalate when a central conclusion depends on methods outside competence, including:
- Complex adaptive, Bayesian, causal, survival, multilevel, spatial, or longitudinal methods
- High-dimensional omics or multiple-testing procedures
- Diagnostic, prediction, or AI evaluation
- Survey weighting or complex sampling
- Economic modeling
- Meta-analysis with dependent effects or network structure
- Unfamiliar qualitative or mixed-methods methodology
- Image forensics, biosecurity, privacy, or domain-specific ethics
Say what expertise is needed and which claim depends on it. Do not mask uncertainty with an automated score.
Raw lines 298 to 312Using the local checklist
Copy assets/statistical_reproducibility_template.json, record evidence locations without pasting manuscript prose into report fields, and run:
python3 scripts/audit_statistics_reproducibility.py local-checklist.jsonStatuses:
verified_presentpartly_documentedmissingnot_assessednot_applicablewith rationale
The tool reports item IDs and counts. It does not calculate merit, rerun analyses, or certify reproducibility.
Raw lines 313 to 329